BACKGROUND: Peak VO2 has traditionally been used for prognostic evaluation in systolic heart failure. However, in the past years, VE/VCO2 slope has been shown to be similar or even superior in many studies. We performed a systematic review and a meta-analysis of diagnostic studies of VE/VCO2 slope to assess its ability to predict cardiovascular events in systolic heart failure. METHODS: We searched the published literature in PubMed and ISI Web of Science for VE/VCO2 slope in heart failure, and performed a systematic review and a meta-analysis of diagnostic studies in articles fulfilling previously established selection criteria. End points were serious cardiovascular events defined as death or the combined end point of death, ventricular assist device implantation, or heart transplant. A sub-analysis was also performed with those articles providing enough data to compare VE/VCO(2) slope prognostic ability to that of peak VO2. RESULTS: Four hundred ninety-one articles that are potentially relevant were identified, and 12 studies were selected based on our predefined criteria. No heterogeneity or evidence of publication bias was found. The 12 studies included a total of 2,628 patients with a mean follow-up of 31 months (95% CI 16-46 months). The combined event rate at 1 year was 11.2% (95% CI 7.8%-14.6%). Diagnostic odds ratio and area under the curve for serious cardiovascular events were 5.02 (95% CI 4.06-6.21) and 0.75 (95% CI 0.72-0.78), respectively. Six studies provided sufficient data for VE/VCO2 slope and peak VO2 comparison. Both variables showed similar performance, although VE/VCO(2) did present a trend to superiority. CONCLUSIONS: In this meta-analysis, VE/VCO2 slope represents a reasonable ability to predict serious cardiovascular events in systolic heart failure, and is at least as effective as peak VO2.
BACKGROUND: Peak VO2 has traditionally been used for prognostic evaluation in systolic heart failure. However, in the past years, VE/VCO2 slope has been shown to be similar or even superior in many studies. We performed a systematic review and a meta-analysis of diagnostic studies of VE/VCO2 slope to assess its ability to predict cardiovascular events in systolic heart failure. METHODS: We searched the published literature in PubMed and ISI Web of Science for VE/VCO2 slope in heart failure, and performed a systematic review and a meta-analysis of diagnostic studies in articles fulfilling previously established selection criteria. End points were serious cardiovascular events defined as death or the combined end point of death, ventricular assist device implantation, or heart transplant. A sub-analysis was also performed with those articles providing enough data to compare VE/VCO(2) slope prognostic ability to that of peak VO2. RESULTS: Four hundred ninety-one articles that are potentially relevant were identified, and 12 studies were selected based on our predefined criteria. No heterogeneity or evidence of publication bias was found. The 12 studies included a total of 2,628 patients with a mean follow-up of 31 months (95% CI 16-46 months). The combined event rate at 1 year was 11.2% (95% CI 7.8%-14.6%). Diagnostic odds ratio and area under the curve for serious cardiovascular events were 5.02 (95% CI 4.06-6.21) and 0.75 (95% CI 0.72-0.78), respectively. Six studies provided sufficient data for VE/VCO2 slope and peak VO2 comparison. Both variables showed similar performance, although VE/VCO(2) did present a trend to superiority. CONCLUSIONS: In this meta-analysis, VE/VCO2 slope represents a reasonable ability to predict serious cardiovascular events in systolic heart failure, and is at least as effective as peak VO2.
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Paul Chase; Daniel Bensimhon; Lawrence P Cahalin; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman Journal: Int J Cardiol Date: 2011-12-19 Impact factor: 4.164
Authors: Lawrence P Cahalin; Paul Chase; Ross Arena; Jonathan Myers; Daniel Bensimhon; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman; Sherry Pinkstaff; Carl J Lavie; Marco Guazzi Journal: Heart Fail Rev Date: 2013-01 Impact factor: 4.214
Authors: Carl J Lavie; Lawrence P Cahalin; Paul Chase; Jonathan Myers; Daniel Bensimhon; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman; Marco Guazzi; Ross Arena Journal: Mayo Clin Proc Date: 2013-02-27 Impact factor: 7.616
Authors: M Correale; T Passero; A Totaro; C A Greco; F De Rosa; M Concilio; S Abbruzzese; G Acanfora; R Ieva; M Di Biase; N D Brunetti Journal: Neth Heart J Date: 2013-01 Impact factor: 2.380